# ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer

> **NCT00415779** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute, Naples** · enrollment: 36 (estimated)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** zoledronic acid

## Key facts

- **NCT ID:** NCT00415779
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2008-12
- **Final completion:** 2009-07
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2010-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00415779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00415779, "ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00415779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*